Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Turning a cancer discovery into a new therapy requires robust evidence, but building that evidence is rarely straightforward. Researchers must establish confidence in potential targets while accounting for tumour heterogeneity, treatment resistance and the limitations of preclinical models. Each can influence whether a potential therapy moves forward.
This live roundtable brings together five cancer researchers to explore how these challenges are addressed in early discovery. The panel will discuss how new targets are identified and validated, what today’s preclinical models can and cannot tell us, and how advances in molecular and cellular research are supporting therapeutic development.
The discussion will draw on the panellists’ work across cancer genomics, metastasis, gene and cytokine therapies, AI-driven proteomics and small-molecule discovery. They will consider where current methods are delivering value, where important gaps remain and what must improve to bring new therapeutic options closer to patients. You’ll also have the opportunity to put your own questions to the panellists during the live Q&A and hear directly from experts working across the field.
Gain a deeper understanding of what is helping cancer discoveries progress towards new therapies and where challenges remain:
Access the free webinar by registering for a membership or logging into your account.
SECURE YOUR PLACE TODAY